Company Overview of Altor BioScience Corporation
Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...
2810 North Commerce Parkway
Miramar, FL 33025-3958
Founded in 2002
Key Executives for Altor BioScience Corporation
Chief Executive Officer, President, and Director
Vice President of Research and Development
Compensation as of Fiscal Year 2015.
Altor BioScience Corporation Key Developments
Altor BioScience Corporation Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
Altor BioScience Corporation Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Altor BioScience Corporation Presents at 2015 BioFlorida Annual Conference, Oct-12-2015 11:40 AM
Sep 29 15
Altor BioScience Corporation Presents at 2015 BioFlorida Annual Conference, Oct-12-2015 11:40 AM. Venue: Omni Orlando Resort at ChampionsGate, 1500 Masters Blvd, ChampionsGate, FL 33896, United States. Speakers: Hing C. Wong, Chief Executive Officer, President, and Director.
Altor BioScience Corporation Announces Efficacy and Safety of Alt-801 for Advanced Bladder Cancer at 2015 Asco Annual Meeting
May 28 15
Altor BioScience Corporation announced that it will present updated safety and efficacy data from its ongoing Phase 1b/2 study of ALT-801 in combination with gemcitabine and cisplatin in patients with advanced or metastatic chemo-refractory urothelial cancer. ALT-801 is a novel proprietary immunotherapy composed of IL-2 genetically fused to a soluble T-cell receptor directed against a p53-derived tumor associated antigen. Altor’s approach uses the TCR to guide IL-2 bioactivity to the tumor site, where the cytokine-stimulated immune system attacks the cancerous cells. ALT-801 exhibits a favorable pharmacokinetic and biodistribution profile, improved efficacy and lower toxicity compared to standard IL-2 treatment in various tumor efficacy models. In early phase clinical testing in patients with metastatic malignancies, ALT-801 was well tolerated in the out-patient setting at dose levels that provided treatment-induced immune responses and clinical benefit to patents. Altor has concluded two Phase 1/2 clinical studies of ALT-801 in combination with gemcitabine and cisplatin or gemcitabine alone in patients with advanced/metastatic urothelial cancer. Altor is also conducting a clinical trial of ALT-801 in combination with gemcitabine in patients with Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|